Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors

Publication date: Available online 6 January 2016
Source:Cancer Genetics
Author(s): S Mukherjee, Z Ma, S Wheeler, M Sathanoori, C Coldren, JL Prescott, N Kozyr, M Bouzyk, M Correll, H Ho, P Chandra, PA Lennon
Development of targeted therapies based on specific genomic alterations have altered the treatment and management of lung and colorectal cancers. Chromosomal microarray (CMA) has allowed identification of copy number variations (CNVs) in lung and colorectal cancers in great detail, and Next-Generation Sequencing (NGS) is used extensively to analyze the genome of cancers for molecular subtyping and use of molecularly guided therapies. The main objective of this study was to evaluate the utility of combining CMA and NGS for a comprehensive genomic assessment of lung and colorectal adenocarcinomas, especially for detecting drug targets. We compared results from NGS and CMA data from 60 lung and 51 colorectal tumors. From CMA analysis, 33% were amplified, 89% showed gains, 75% showed losses and 41% demonstrated loss of heterozygosity; pathogenic variants were identified in 81% of colon and 67% lung specimens through NGS. KRAS mutations commonly occurred with loss in TP53 and there was significant loss of BRCA1 and NF1 among male patients with lung cancer. For clinically actionable targets, 23% had targetable CNVs when no pathogenic variants were detected by NGS. The data thus indicates that combining the two approaches provides significant benefit in a routine clinical setting not available by NGS alone.

from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader http://ift.tt/1ZbFBsN
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1ZbMnik
via IFTTT